GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » ROE %

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) ROE % : Negative Equity% (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Parnell Pharmaceuticals Holdings's annualized net income for the quarter that ended in Dec. 2018 was $0.09 Mil. Parnell Pharmaceuticals Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2018 was $-10.97 Mil. Therefore, Parnell Pharmaceuticals Holdings's annualized ROE % for the quarter that ended in Dec. 2018 was Negative Equity%.

The historical rank and industry rank for Parnell Pharmaceuticals Holdings's ROE % or its related term are showing as below:

PARNF's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 4.2
* Ranked among companies with meaningful ROE % only.

Parnell Pharmaceuticals Holdings ROE % Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings ROE % Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
ROE %
Get a 7-Day Free Trial -88.47 -40.54 -154.72 - Negative Equity

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
ROE % Get a 7-Day Free Trial -47.13 -40.54 -154.72 - Negative Equity

Competitive Comparison of Parnell Pharmaceuticals Holdings's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's ROE % falls into.



Parnell Pharmaceuticals Holdings ROE % Calculation

Parnell Pharmaceuticals Holdings's annualized ROE % for the fiscal year that ended in Dec. 2018 is calculated as

ROE %=Net Income (A: Dec. 2018 )/( (Total Stockholders Equity (A: Dec. 2017 )+Total Stockholders Equity (A: Dec. 2018 ))/ count )
=0.093/( (-8.652+-13.282)/ 2 )
=0.093/-10.967
=Negative Equity %

Parnell Pharmaceuticals Holdings's annualized ROE % for the quarter that ended in Dec. 2018 is calculated as

ROE %=Net Income (Q: Dec. 2018 )/( (Total Stockholders Equity (Q: Dec. 2017 )+Total Stockholders Equity (Q: Dec. 2018 ))/ count )
=0.093/( (-8.652+-13.282)/ 2 )
=0.093/-10.967
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (Dec. 2018) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2018 )
=Net Income/Total Stockholders Equity
=0.093/-10.967
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0.093 / 19.031)*(19.031 / 23.5475)*(23.5475 / -10.967)
=Net Margin %*Asset Turnover*Equity Multiplier
=0.49 %*0.8082*N/A
=ROA %*Equity Multiplier
=0.4 %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2018 )
=Net Income/Total Stockholders Equity
=0.093/-10.967
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (0.093 / 0.242) * (0.242 / 2.451) * (2.451 / 19.031) * (19.031 / 23.5475) * (23.5475 / -10.967)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.3843 * 0.0987 * 12.88 % * 0.8082 * N/A
=Negative Equity %

Note: The net income data used here is one times the annual (Dec. 2018) net income data. The Revenue data used here is one times the annual (Dec. 2018) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Parnell Pharmaceuticals Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.